Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke

Tissue plasminogen activator (tPA) has been shown to improve 3-month outcome in stroke patients treated within 3 hours of symptom onset. The costs associated with this new treatment will be a factor in determining the extent of its utilization. Data from the NINDS rt-PA Stroke Trial and the medical literature were used to estimate the health and economic outcomes associated with using tPA in acute stroke patients. A Markov model was developed to estimate the costs per 1,000 patients eligible for treatment with tPA compared with the costs per 1,000 untreated patients. One-way and multiway sensitivity analyses (using Monte Carlo simulation) were performed to estimate the overall uncertainty of the model results. In the NINDS rt-PA Stroke Trial, the average length of stay was significantly shorter in tPA-treated patients than in placebo-treated patients (10.9 versus 12.4 days; p = 0.02) and more tPA patients were discharged to home than to inpatient rehabilitation or a nursing home (48% versus 36%;p = 0.002). The Markov model estimated an increase in hospitalization costs of $1.7 million and a decrease in rehabilitation costs of $1.4 million and nursing home cost of $4.8 million per 1,000 eligible treated patients for a health care system that includes acute through long-term care facilities. Multiway sensitivity analysis revealed a greater than 90% probability of cost savings. The estimated impact on long-term health outcomes was 564 (3 to 850) quality-adjusted life-years saved over 30 years of the model per 1,000 patients. Treating acute ischemic stroke patients with tPA within 3 hours of symptom onset improves functional outcome at 3 months and is likely to result in a net cost savings to the health care system.

[1]  P. Yablon,et al.  Retail dentistry - tidal wave or ripple? How will it affect traditional dental practice? , 1982, The Dialog.

[2]  P A Wolf,et al.  Survival and recurrence following stroke. The Framingham study. , 1982, Stroke.

[3]  R. Bloch,et al.  Interobserver agreement for the assessment of handicap in stroke patients. , 1988, Stroke.

[4]  David M. Eddy,et al.  Practice Policies—Guidelines for Methods , 1990 .

[5]  J. Broderick,et al.  Epidemiological Characteristics of Lacunar Infarcts in a Population , 1991, Stroke.

[6]  W. Mcghan,et al.  Evaluating the Cost Impact of Intravenous Antibiotic Dosing Frequencies , 1991, DICP : the annals of pharmacotherapy.

[7]  B. Levin,et al.  Transcranial Doppler Assessment of Cerebral Flow Velocity During Cognitive Tasks , 1992, Stroke.

[8]  Carl V. Granger,et al.  Discharge Outcome After Stroke Rehabilitation , 1992, Stroke.

[9]  J. Rothrock,et al.  Ultra-rapid identification, triage, and enrollment of stroke patients into clinical trials. , 1994, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[10]  J. Lee,et al.  Patient Preferences for Stroke Outcomes , 1994, Stroke.

[11]  R. Sacco,et al.  Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community , 1994, Neurology.

[12]  C. Nair,et al.  Epidemiology of stroke in Canada. , 1994, Health reports.

[13]  G. Oster,et al.  Cost‐effectiveness of Ticlopidine in Preventing Stroke in High‐risk Patients , 1994, Stroke.

[14]  M. Alexander.  Stroke Rehabilitation Outcome: A Potential Use of Predictive Variables to Establish Levels of Care , 1994, Stroke.

[15]  J. Sinacore,et al.  Stroke Inpatient Rehabilitation: A Comparison across Age Groups , 1994, Journal of the American Geriatrics Society.

[16]  R. Ackerman,et al.  Identifying clinically relevant carotid disease. , 1994, Stroke.

[17]  Erry,et al.  Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. , 1995, The New England journal of medicine.

[18]  C. Bishop.  Sharing the Burden: Strategies for Public and Private Long-Term Care Insurance , 1995 .

[19]  B. Dobkin,et al.  The economic impact of stroke. , 1995, Neurology.

[20]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[21]  M. Levitt,et al.  A Comparison of Symptoms after the Consumption of Milk or Lactose-Hydrolyzed Milk by People with Self-Reported Severe Lactose Intolerance , 1995 .

[22]  Joseph H. Huber,et al.  Poststroke rehabilitation in older Americans. The Medicare experience. , 1996, Medical care.

[23]  E. Nussbaum,et al.  Cost-effectiveness of carotid endarterectomy. , 1996, Neurosurgery.

[24]  J. Rinne,et al.  Analysis of 561 patients with 690 middle cerebral artery aneurysms: anatomic and clinical features as correlated to management outcome. , 1996, Neurosurgery.

[25]  J Lipscomb,et al.  Inpatient costs of specific cerebrovascular events at five academic medical centers. , 1996, Neurology.

[26]  J. Holmes,et al.  Lifetime cost of stroke in the United States. , 1996, Stroke.

[27]  L D Lunsford,et al.  Factors that predict the bleeding risk of cerebral arteriovenous malformations. , 1996, Stroke.

[28]  K. Welch,et al.  Total quality improvement method for reduction of delays between emergency department admission and treatment of acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1997, Archives of neurology.

[29]  Penisten Dk.  The history of optometry in America: information waiting to be found. , 1997 .

[30]  J. Grotta,et al.  Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice. , 1998, Stroke.